Amerasham Pharmacia Biotech AB – Trademark Portfolio
Entity Type: 03
Amerasham Pharmacia Biotech AB holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include GYROS. The owner is based in SE-751 84 Uppsala.
Bjorkgatan 30
SE-751 84 Uppsala , SE
Showing of trademarks Trademarks
Trademark Classifications
Amerasham Pharmacia Biotech AB's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Amerasham Pharmacia Biotech AB have?
Amerasham Pharmacia Biotech AB has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Amerasham Pharmacia Biotech AB file in?
Amerasham Pharmacia Biotech AB files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Amerasham Pharmacia Biotech AB's most well-known trademarks?
Amerasham Pharmacia Biotech AB's registered trademark portfolio includes well-known marks such as GYROS. These are among 1 currently registered trademark in the portfolio.
What is Amerasham Pharmacia Biotech AB's trademark registration success rate?
Amerasham Pharmacia Biotech AB has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.